| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print August 27, 2002
Am J Physiol Endocrinol Metab, 10.1152/ajpendo.00189.2002
Submitted on May 3, 2002
Accepted on August 12, 2002
1 Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Biokinesiology, University of Southern California, Los Angeles, CA, USA
2 Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
3 Department of Medicine, Indiana University, Indiana, IN, USA
* To whom correspondence should be addressed. E-mail: fsattler{at}hsc.usc.edu.
Thirty HIV infected men were randomized to high dose nandrolone decanoate weekly (Group-1) or nandrolone plus resistance training (Group-2) for 12 weeks. For the two groups, nandrolone had no significant effects on total cholesterol, LDL-cholesterol, LDL phenotype, or fasting triglycerides, although triglycerides decreased by 66±124 mg/dL for the entire population (p=0.01). Group-2 subjects had a favorable increase of 5.2±7.7 angstroms in LDL particle size (p=0.03), where as there was no change in Group-1. Lipoprotein (a) decreased by 7.3±6.8 mg/dL for Group-1 (p=0.002) and by 6.9±8.1 for Group-2 (p=0.013). However, HDL-cholesterol decreased by 8.7±7.4 mg/dL for Group-1 (p<0.001) and by 10.6±5.9 for Group-2 (p<0.001). Percentages of HDL2b [9.7-12 nm] and HDL2a [8.8-9.7 nm] subfractions decreased similarly for the two groups, whereas HDL3a [8.2-8.8 nm] and HDL3b [7.8-8.2 nm] increased in the groups during study therapy (p
0.02 for all comparisons). There was no evidence of a decrease insulin sensitivity in either group. Whereas, fasting glucose, fasting insulin, and HOMA-IR improved in Group-2 (p<0.05). These metabolic effects were favorable (other than HDL) but changes were generally transient (except for HDL in Group-2) with measurements returning to baseline two months after the interventions were completed.
This article has been cited by other articles:
|
|
 |
|
  K. Mulligan, R. Zackin, R. A. Clark, B. Alston-Smith, T. Liu, F. R. Sattler, T. B. Delvers, J. S. Currier, and for the AIDS Clinical Trials Group 329 Study Team Effect of Nandrolone Decanoate Therapy on Weight and Lean Body Mass in HIV-Infected Women With Weight Loss: A Randomized, Double-blind, Placebo-Controlled, Multicenter Trial Arch Intern Med, March 14, 2005; 165(5): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J Batterham Investigating heterogeneity in studies of resting energy expenditure in persons with HIV/AIDS: a meta-analysis Am. J. Clinical Nutrition, March 1, 2005; 81(3): 702 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cuerda, A. Zugasti, I. Breton, M. Camblor, P. Miralles, and P. Garcia Treatment With Nandrolone Decanoate and Megestrol Acetate in HIV-Infected Men Nutr Clin Pract, February 1, 2005; 20(1): 93 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Schroeder, L. Zheng, K. E. Yarasheski, D. Qian, Y. Stewart, C. Flores, C. Martinez, M. Terk, and F. R. Sattler Treatment with oxandrolone and the durability of effects in older men J Appl Physiol, March 1, 2004; 96(3): 1055 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Evans Current Concepts in Anabolic-Androgenic Steroids Am. J. Sports Med., March 1, 2004; 32(2): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Schroeder, M. Terk, and F. R. Sattler Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E16 - E24. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
